Increased risk of urinary calculi in patients with migraine: A nationwide cohort study

Tsai, Min Juei; Chen, Yung Tai; Ou, Shuo Ming; Shin, Chia Jen; Peng, Kuan‐Po; Tang, Chao Hsiun; Wang, Shuu Jiun

doi:10.1177/0333102414553825

Cited by 8 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NSAIDs are known to be strongly associated with CKD due to the inhibition of cyclo-oxygenase activity, 33 but whether anti-migraine agents are independent risk factors of CKD remains under debate. 34–36 Although topiramate administration was reported to have an associated risk of urinary calculi, 22 we did not find a significant risk of incident CKD in subjects with migraine.…”

Section: Discussioncontrasting

confidence: 66%

“…Migraine was defined as at least three records of a migraine diagnostic code made by a neurology specialist within 1 year (A-code A229 and ICD-9-CM codes 346.x, online supplementary table S1 ). 22 We defined various diseases, for example, migraine, CKD or comorbid conditions, using diagnostic codes (online supplementary table S1 ). These diagnostic codes were from ambulatory visit records and principal diagnosis.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study

Weng

Kor

et al. 2017

BMJ Open

View full text Add to dashboard Cite

ObjectiveWe compared the incidence and risk of chronic kidney disease (CKD) between subjects with new-onset migraine and matched controls without migraine in this large-scale retrospective cohort study.DesignPopulation-based cohort study.Setting8880 subjects with migraine and 503 070 subjects without migraine were enrolled between January 1, 2000 and December 31, 2013, all diagnosed to be without kidney disease. All the participants were registered in the National Health Insurance Research Database.ParticipantsFinally, data from 7156 subjects with migraine and 7156 propensity-score-matched control subjects were analysed.Primary outcome measureWe used Cox proportional hazards regression to estimate adjusted HRs for incident CKD; subgroup analyses were performed to assess the interactive effects of migraine with demographics, comorbidities and long-term medications.ResultsThe incidence of CKD was higher in the migraine group than in the control group. The risk of developing CKD was significantly higher in subjects with migraine than without migraine (P=0.031). Subjects with migraine aged <65 years (age 40–64 (adjusted HR (aHR) 1.35; 95% CI 1.05 to 1.73); age <40 (aHR 1.55; 95% CI 1.02 to 2.36)), with ≥1 comorbid diseases (1–2 diseases (aHR 1.30; 95% CI 1.01 to 1.68); ≥3 diseases (aHR 1.45; 95% CI 1.01 to 2.07)), and not receiving anti-migraine agents (aHR 1.26; 95% CI 1.04 to 1.54) were at a higher risk of developing CKD compared with the control subjects. The interaction between migraine and comorbidities was not significant; age, male gender and long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) were independent risk factors for CKD in subjects with migraine.ConclusionMigraine may be an independent risk factor for CKD. Young subjects with migraine, and those with comorbid conditions or without medical control, are likely to be at higher risk for CKD. Ageing, male sex and NSAIDs tend to have an association with CKD in subjects with migraine.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Methodsmentioning

confidence: 99%

Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study

Weng

Kor

et al. 2017

BMJ Open

View full text Add to dashboard Cite

show abstract

“…To assess the risk of urolithiasis occurrence with topiramate exposure in clinical practice, a population‐based study compared a cohort of patients (epilepsy and migraine) receiving topiramate and matched controls, finding no significant difference between groups . A separate population cohort study compared urolithiasis in individuals with migraine and matched controls without migraine . Migraineurs were at significantly increased risk of developing urinary calculi, independent of topiramate exposure.…”

Section: Tolerability/safetymentioning

confidence: 99%

Topiramate in Migraine Prevention: A 2016 Perspective

Silberstein

2016

Headache

103

View full text Add to dashboard Cite

Topiramate has activity at multiple molecular targets, which may account for why it is effective in migraine and most other, more specific, anticonvulsants are not. Based on randomized controlled trials, topiramate reduces migraine frequency and acute medication use, improves quality of life, and reduces disability in patients with episodic migraine and in those with chronic migraine with or without medication overuse headache. Its efficacy in chronic migraine is not improved by the addition of propranolol. Topiramate's ability to prevent progression from high-frequency episodic migraine to chronic migraine remains unclear. Consistent with clinicians' perceptions, migraineurs are more sensitive to topiramate-associated side effects than patients with epilepsy. Paresthesia is a common occurrence early in treatment but is rarely cause for terminating topiramate treatment. Cognitive problems occur much less frequently than paresthesia but are more troublesome in terms of treatment discontinuation. Cognitive complaints can often be managed by slowly increasing the topiramate dose in small increments to allow habituation. As with other carbonic anhydrase inhibitors, topiramate has metabolic effects that favor the development of metabolic acidosis and possibly renal stones. Because migraineurs have an increased risk of renal stones independent of topiramate exposure, clinicians should counsel all migraine patients to maintain hydration. Abrupt onset of blurring, other visual disturbances, and/or ocular pain following topiramate's initiation should be evaluated promptly since this may indicate rare but potentially sight-threatening idiosyncratic events. Postmarketing evidence has shown that first-trimester exposure to topiramate monotherapy is associated with increased occurrence of cleft lip with or without cleft palate (Pregnancy Category D). Even though topiramate's long half-life would seemingly support q.d. dosing, randomized controlled migraine trials used b.i.d. administration of immediate-release (IR) topiramate, which has more favorable plasma concentration-time profile (ie, lower peak concentrations and higher trough concentrations) than q.d. IR dosing. Given the sensitivity of migraineurs to topiramate-related adverse events, particularly cognitive effects, pharmacokinetic profiles should be considered when optimizing migraine outcomes. The extended-release (XR) formulations Qudexy XR (Upsher-Smith Laboratories) and Trokendi XR (Supernus Pharmaceuticals) were specifically designed to achieve the adherence benefits of q.d. dosing but with more favorable (ie, more constant) steady-state plasma concentrations over the 24-hour dosing interval vs IR topiramate b.i.d. Intriguing results from a study in healthy volunteers showed consistently less impairment in neuropsychometric tests of verbal fluency and mental processing speed with an XR topiramate formulation (Trokendi XR) vs IR topiramate b.i.d. These findings suggest a pharmacodynamic effect associated with significantly reducing plasma concentration fluctuatio...

show abstract

“…[8][9][10] Therefore, in this study, we aimed to investigate the correlation of AS with nephrolithiasis by performing a nationwide population-based cohort study.…”

mentioning

confidence: 99%

The Risk of Nephrolithiasis Among Patients With Ankylosing Spondylitis: a Population-Based Cohort Study

Shih¹,

Tang²,

Lung³

et al. 2016

Arch Rheumatol

View full text Add to dashboard Cite

Objectives: This study aims to investigate the correlation of ankylosing spondylitis (AS) with nephrolithiasis by performing a nationwide populationbased cohort study. Patients and methods:The data used in this retrospective cohort study were collected from the Taiwan National Health Insurance Research database. The study included a total of 3,334 AS patients (1,914 males, 1,420 females; mean age 44.51±16.83 years; range 22 to 79 years) and 13,336 non-AS patients (7,656 males, 5,680 females; mean age 44.27±17.01 years; range 21 to 78 years) who had been followed-up on an average of 6.78 years and 6.75 years, respectively, between January 2000 and December 2008. Results: The percentage of newly diagnosed nephrolithiasis was 4.8% in all study subjects. However, the percentages of newly diagnosed nephrolithiasis were 5.76% and 4.58% in the AS and non-AS cohorts, respectively. After adjusting the patients' sex, age, urbanization level, and comorbidities, the hazard ratio obtained from our multivariable Cox model was 1.19. Conclusion: Our study findings indicate that patients with AS are more likely to develop nephrolithiasis than non-AS patients.

show abstract

Increased risk of urinary calculi in patients with migraine: A nationwide cohort study

Abstract: Our study showed migraine was associated with an increased risk of urinary calculi, independent of topiramate use. A higher frequency of clinic visits was associated with a greater risk.

Cited by 8 publications

References 41 publications

Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study

Migraine and subsequent chronic kidney disease risk: a nationwide population-based cohort study

Topiramate in Migraine Prevention: A 2016 Perspective

The Risk of Nephrolithiasis Among Patients With Ankylosing Spondylitis: a Population-Based Cohort Study

Contact Info

Product

Resources

About